Gemtuzumab Ozogamicin Production Cost Reports

The report provides a detailed analysis essential for establishing a gemtuzumab ozogamicin production plant. It encompasses all critical aspects necessary for gemtuzumab ozogamicin production, including the cost of gemtuzumab ozogamicin production, gemtuzumab ozogamicin plant cost, gemtuzumab ozogamicin production costs, and the overall gemtuzumab ozogamicin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a gemtuzumab ozogamicin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Gemtuzumab ozogamicin is the scientific (generic) name of the antibody–drug conjugate, which is marketed under the brand name of Mylotarg. It is primarily used for the treatment of CD33-positive acute myeloid leukaemia (AML) in adults and pediatric patients. It is an antibody-drug conjugate, which means it combines an antibody that seeks out cancer cells with a chemical agent that kills them.

The drug combines a monoclonal antibody with a chemotherapy agent, which allows it to deliver the cancer-killing substance directly to leukaemia cells while limiting damage to healthy cells. It is commonly used as part of combination therapy or as a standalone treatment in specific patient groups, including newly diagnosed and relapsed cases. It also plays an important role in improving treatment outcomes and supporting advances in targeted cancer therapies.

The market for gemtuzumab ozogamicin is predominantly driven by its application as a targeted cancer drug approved for treating certain leukaemias, which boosts its demand in the oncology sector. Its application as a drug for the treatment of acute myeloid leukaemia (AML), especially in patients whose cancer cells express the CD33 protein, also fuels its demand in the pharmaceutical industry. Its demand as a drug in both newly diagnosed and relapsed AML cases for its selective action, which helps reduce damage to healthy cells, also promotes its market growth. Its usage in combination with other chemotherapy drugs to improve treatment effectiveness further supports its demand in the medical and healthcare sectors.

Increasing preference for targeted and antibody-based therapies, and supportive regulatory approvals, further contribute to its demand. Industrial gemtuzumab ozogamicin procurement depends on factors such as the high cost of biologic production, strict regulatory requirements, availability of specialised raw materials, and the need for controlled production conditions. Progress in biopharmaceutical production, reliable suppliers, and efficient distribution systems also continue to shape its global procurement processes.

Raw Material for Gemtuzumab Ozogamicin Production

According to the gemtuzumab ozogamicin production plant project report, the major raw materials for gemtuzumab ozogamicin production include Genetically engineered NS0 myeloma cells and Calicheamicin (Fermentation product from Micromonospora echinospora subsp. calichensis). 

Production Process of Gemtuzumab Ozogamicin

The extensive gemtuzumab ozogamicin production cost report consists of the following industrial production process:

1. Production via Bioconjugation: The production process of gemtuzumab ozogamicin begins with growing the humanised IgG4 kappa anti-CD33 antibody (hP67.6) in a mammalian cell suspension culture using an NS0 myeloma cell line. The cells produce and secrete the antibody into the culture medium. The antibody is then harvested and purified through a controlled downstream process designed to both clean up the product and address viral safety. The process includes a low pH treatment step, DEAE-Sepharose chromatography, and viral filtration to inactivate or remove potential retroviruses. In parallel, the cytotoxic payload calicheamicin is obtained by fermenting the bacterium Micromonospora echinospora subsp. calichensis and then isolating and purifying the antibiotic. After both components meet quality requirements, the purified antibody is chemically linked to calicheamicin to form the antibody–drug conjugate. Further, the steps of final purification, formulation, sterile filtration, and fill-finish result in the production of gemtuzumab ozogamicin as the final drug product.

Gemtuzumab oOzogamicin is a recombinant humanised anti-CD33 monoclonal antibody conjugated to the cytotoxic antitumor antibiotic calicheamicin. It appears as a sterile, white to off-white, preservative-free lyophilised cake or powder that is reconstituted for intravenous administration. The molecular weight of the compound is approximately 152 to 153 kDa. Other properties, such as density, melting point, boiling point, and flash point, are not applicable to this biological macromolecule. The compound consists of conjugated and unconjugated gemtuzumab molecules. The most frequently reported toxicities include severe myelosuppression, with nearly all patients experiencing neutropenia, thrombocytopenia, and anaemia, as well as hepatotoxicity, including potentially fatal hepatic veno-occlusive disease. Additionally, infusion-related reactions, infections, haemorrhage, nausea, and mucositis have been reported. It is recommended that patients receive premedication with a corticosteroid, antihistamine, and acetaminophen prior to each dose, and continuous monitoring for signs of hepatic veno-occlusive disease is essential during treatment.